OKYO Pharma (OKYO) Non-cash Items (2024 - 2025)
OKYO Pharma (OKYO) reported Non-cash Items of $2.0 million for Q3 2025, up 250.97% year-over-year from $558921.0 in Q3 2024, and up 250.97% quarter-over-quarter from $558921.0 in Q3 2024.
OKYO Pharma (OKYO) Non-cash Items (2024 - 2025) Analysis & Trends
OKYO Pharma (OKYO) has 2 years of Non-cash Items data on file, last reported at $2.0 million in Q3 2025.
- Non-cash Items for Q3 2025 came in at $2.0 million, up 250.97% year-over-year; the trailing twelve-month figure through Sep 2025 was $2.0 million (up 250.97% YoY), and the FY2025 annual result was $2.0 million, changed N/A from the prior year.
- Non-cash Items grew to $2.0 million in Q3 2025 per OKYO's latest filing, from $558921.0 in the prior quarter.
- Over five years, Non-cash Items peaked at $2.0 million in Q3 2025 and troughed at $558921.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - |
| 10 | OKYO Pharma | 244.98 Mn | 240.76 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 1.96 Mn |
| Sep 30, 2025 | 1.96 Mn |
| Sep 30, 2024 | 558,921.00 |
| Sep 30, 2024 | 558,921.00 |